LGD-4033 and Primobolan Interaction
LGD-4033 and Primobolan have a potentially harmful interaction with 64% confidence. Both LGD-4033 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.
Compound Profiles
LGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profilePrimobolan
Anabolic Steroid | Lean Mass & Low Side Effect Profile
Metenolone binds to the androgen receptor (AR) to promote nitrogen retention, protein synthesis, and anti-catabolic effects in skeletal muscle tissue. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, meaning it produces no estrogenic metabolites and does not contribute to water retention, gynecomastia, or estrogen-mediated fat gain.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take LGD-4033 with Primobolan?
Combining LGD-4033 with Primobolan is not recommended. Both LGD-4033 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is LGD-4033 and Primobolan safe together?
This combination carries significant risk. Both LGD-4033 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between LGD-4033 and Primobolan?
Both LGD-4033 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.
How should I time LGD-4033 and Primobolan?
LGD-4033 has a half-life of ~24-36 hours and Primobolan has a half-life of ~10 days (enanthate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.